NASDAQ:IKT Inhibikase Therapeutics Q4 2025 Earnings Report $2.24 -0.07 (-2.83%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inhibikase Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.12Beat/MissBeat by +$0.03One Year Ago EPSN/AInhibikase Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibikase Therapeutics Announcement DetailsQuarterQ4 2025Date3/26/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Inhibikase Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Nuvation Bio (NUVB)September 18 at 9:19 AM | theglobeandmail.comInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityAugust 11, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 21 at 1:00 AM | Base Camp Trading (Ad)Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHJuly 23, 2026 | globenewswire.comInhibikase sells $50M of common stock to RA CapitalJuly 14, 2026 | msn.comInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) FacilityJuly 14, 2026 | globenewswire.comSee More Inhibikase Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email. Email Address About Inhibikase TherapeuticsInhibikase Therapeutics (NASDAQ:IKT) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases associated with abnormal protein accumulation and misfolding. The company’s research is centered primarily on neurodegenerative disorders involving alpha-synuclein, a protein implicated in Parkinson’s disease and related conditions. Inhibikase’s lead investigational product, IkT-148009, is an orally administered, brain-penetrant Abelson tyrosine kinase inhibitor. The company is evaluating the compound as a potential treatment for Parkinson’s disease and other synucleinopathies, including multiple system atrophy. Its development strategy is intended to address both disease progression and the underlying biological mechanisms associated with alpha-synuclein pathology. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase conducts research and clinical development activities through collaborations with academic institutions, research organizations and clinical investigators. The company’s programs remain investigational, and its products have not been approved for commercial use by regulatory authorities.View Inhibikase Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street Support3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth3 Overlooked Tech Names Quietly Powering Everyday Life Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
